Sign in
CompletedPhase 2

Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery

Key facts

Who runs it
Benha University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
75 people enrolled
Started
26 Feb 2026
Ended
24 Aug 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dexmedetomidine (Low dose)
  • Dexmedetomidine (High dose)
  • Fentanyl
Record updated
25 August 2026

Who can take part

Age
55 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Elderly surgical patients
  • ASA physical status grade II-III
  • Planned major lower limb orthopedic surgery

Who cannot take part

  • pre-existing dementia or drug allergies

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates the dose-response relationship of Dexmedetomidine (DEX) in reducing the incidence and severity of postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) in elderly patients. The study compares different doses of DEX against a fentanyl control group in patients undergoing major lower limb orthopedic surgery under general anesthesia to determine the optimal dosage for cognitive protection.

The 3 groups in the trial

  • DEX Group 1 (Low Dose)Existing treatment, for comparison

    Patients receive a specific low-dose intravenous infusion of Dexmedetomidine during major lower limb orthopedic surgery under opioid-based general anesthesia. The intervention aims to evaluate the dose-response relationship regarding its neuroprotective effects on postoperative delirium (POD).

    Treatment: Dexmedetomidine (Low dose)

  • DEX Group 1 (High Dose)Existing treatment, for comparison

    Patients receive a higher-dose intravenous infusion of Dexmedetomidine during the surgical procedure. This arm is designed to determine if higher concentrations of DEX provide a more significant reduction in the incidence and severity of postoperative delirium and cognitive dysfunction compared to the lower dose.

    Treatment: Dexmedetomidine (High dose)

  • Control GroupExisting treatment, for comparison

    Patients in this group receive standard opioid-based general anesthesia using fentanyl without the addition of Dexmedetomidine. This group serves as the baseline to compare the efficacy of DEX in preventing cognitive decline.

    Treatment: Fentanyl

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dose-Effect Relationship of Dexmedetomidine on Delirium and Cognitive Function After Lower Limb Orthopedic Surgeries for Elderly Patients
Record updated
25 August 2026